Literature DB >> 23212265

PDCD4 expression in thyroid neoplasia.

Gianmaria Pennelli1, Matteo Fassan, Caterina Mian, Marco Pizzi, Mariangela Balistreri, Susi Barollo, Francesca Galuppini, Vincenza Guzzardo, Mariarosa Pelizzo, Massimo Rugge.   

Abstract

Both the morphogenesis and the molecular pathways of thyroid cancers are controversial. Programmed cell death 4 (PDCD4) is a tumor suppressor gene whose expression is controlled by miR-21. By applying immunohistochemistry for PDCD4 and both quantitative real-time PCR (qRT-PCR) and in situ hybridization for miR-21, this study explored PDCD4 expression in human follicular-cell-derived thyroid neoplastic lesions. PDCD4 protein expression was semiquantitatively assessed in 100 consecutive thyroid tumors (25 follicular adenomas (FA), 25 follicular carcinomas (FC), 25 papillary carcinomas (PC), and 25 poorly-differentiated/anaplastic cancers (PD-AC)). Twenty-five additional nonneoplastic thyroid tissue samples were included as controls. To further support the data, miR-21 expression was tested (by qRT-PCR and in situ hybridization) in a different series of 75 cases (15 FAs, 15 FCs, 15 PCs, 15 PD-ACs, and 15 controls). Nonneoplastic thyrocytes consistently featured a strong nuclear PDCD4 expression, while the protein's expression was significantly downregulated in neoplastic epithelia. PDCD4 downregulation was significantly associated with less well-differentiated cancer phenotypes (p < 0.001) and more advanced tumor stages (p < 0.001). Consistently with PDCD4 downregulation, miR-21 was upregulated in neoplastic by comparison with nonneoplastic tissue samples. The present results provide evidence of PDCD4 having a role in thyroid carcinogenesis; further studies should investigate the diagnostic value and the prognostic impact of PDCD4 in thyroid neoplasia.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23212265     DOI: 10.1007/s00428-012-1352-6

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  21 in total

1.  PDCD4 nuclear loss inversely correlates with miR-21 levels in colon carcinogenesis.

Authors:  Matteo Fassan; Marco Pizzi; Luciano Giacomelli; Claudia Mescoli; Kathrin Ludwig; Salvatore Pucciarelli; Massimo Rugge
Journal:  Virchows Arch       Date:  2011-01-29       Impact factor: 4.064

2.  microRNA-145 in Barrett's oesophagus: regulating BMP4 signalling via GATA6.

Authors:  Jantine W P M van Baal; Romy E Verbeek; Pauline Bus; Matteo Fassan; Rhonda F Souza; Massimo Rugge; Fiebo J W ten Kate; Frank P Vleggaar; Peter D Siersema
Journal:  Gut       Date:  2012-04-13       Impact factor: 23.059

3.  Programmed cell death 4 nuclear loss and miR-21 or activated Akt overexpression in esophageal squamous cell carcinogenesis.

Authors:  M Fassan; S Realdon; M Pizzi; M Balistreri; G Battaglia; G Zaninotto; E Ancona; M Rugge
Journal:  Dis Esophagus       Date:  2011-08-24       Impact factor: 3.429

Review 4.  Workup of well-differentiated thyroid carcinoma.

Authors:  Cristian M Slough; Gregory W Randolph
Journal:  Cancer Control       Date:  2006-04       Impact factor: 3.302

5.  American Association of Clinical Endocrinologists and Associazione Medici Endocrinologi medical guidelines for clinical practice for the diagnosis and management of thyroid nodules.

Authors:  Hossein Gharib; Enrico Papini; Roberto Valcavi; H Jack Baskin; Anna Crescenzi; Massimo E Dottorini; Daniel S Duick; Rinaldo Guglielmi; Carlos Robert Hamilton; Martha A Zeiger; Michele Zini
Journal:  Endocr Pract       Date:  2006 Jan-Feb       Impact factor: 3.443

Review 6.  Anaplastic thyroid carcinoma: current diagnosis and treatment.

Authors:  D Giuffrida; H Gharib
Journal:  Ann Oncol       Date:  2000-09       Impact factor: 32.976

7.  Epidermal expression of the translation inhibitor programmed cell death 4 suppresses tumorigenesis.

Authors:  Aaron P Jansen; Corinne E Camalier; Nancy H Colburn
Journal:  Cancer Res       Date:  2005-07-15       Impact factor: 12.701

8.  Programmed cell death 4 protein in esophageal cancer.

Authors:  Matteo Fassan; Matteo Cagol; Gianmaria Pennelli; Christian Rizzetto; Luciano Giacomelli; Giorgio Battaglia; Giovanni Zaninotto; Ermanno Ancona; Alberto Ruol; Massimo Rugge
Journal:  Oncol Rep       Date:  2010-07       Impact factor: 3.906

9.  Loss of PDCD4 expression in human lung cancer correlates with tumour progression and prognosis.

Authors:  Yuan Chen; Thomas Knösel; Glen Kristiansen; Agnieszka Pietas; Mitchell E Garber; Sachiko Matsuhashi; Iwata Ozaki; Iver Petersen
Journal:  J Pathol       Date:  2003-08       Impact factor: 7.996

10.  Loss of programmed cell death 4 expression marks adenoma-carcinoma transition, correlates inversely with phosphorylated protein kinase B, and is an independent prognostic factor in resected colorectal cancer.

Authors:  Giridhar Mudduluru; Fabian Medved; Rainer Grobholz; Camela Jost; Anette Gruber; Joerg H Leupold; Stefan Post; Aaron Jansen; Nancy H Colburn; Heike Allgayer
Journal:  Cancer       Date:  2007-10-15       Impact factor: 6.860

View more
  9 in total

Review 1.  Deregulation of microRNA expression in thyroid neoplasias.

Authors:  Pierlorenzo Pallante; Sabrina Battista; Giovanna Maria Pierantoni; Alfredo Fusco
Journal:  Nat Rev Endocrinol       Date:  2013-11-19       Impact factor: 43.330

2.  Roles of phosphatidylinositol 3-kinase regulatory subunit alpha, activator protein-1, and programmed cell death 4 in diagnosis of papillary thyroid carcinoma.

Authors:  Xiaojun Chen; Wenjun Wu; Xiong Chen; Xiaohua Gong
Journal:  Tumour Biol       Date:  2015-12-04

Review 3.  The role of microRNAs in different types of thyroid carcinoma: a comprehensive analysis to find new miRNA supplementary therapies.

Authors:  S Pishkari; M Paryan; M Hashemi; E Baldini; S Mohammadi-Yeganeh
Journal:  J Endocrinol Invest       Date:  2017-07-31       Impact factor: 4.256

4.  Identification of potential therapeutic targets for papillary thyroid carcinoma by bioinformatics analysis.

Authors:  Ming Zhao; Ke-Jing Wang; Zhuo Tan; Chuan-Ming Zheng; Zhong Liang; Jian-Qiang Zhao
Journal:  Oncol Lett       Date:  2015-10-26       Impact factor: 2.967

5.  Oncogenic transformation of human lung bronchial epithelial cells induced by arsenic involves ROS-dependent activation of STAT3-miR-21-PDCD4 mechanism.

Authors:  Poyil Pratheeshkumar; Young-Ok Son; Sasidharan Padmaja Divya; Lei Wang; Zhuo Zhang; Xianglin Shi
Journal:  Sci Rep       Date:  2016-11-23       Impact factor: 4.379

6.  Hexavalent chromium induces malignant transformation of human lung bronchial epithelial cells via ROS-dependent activation of miR-21-PDCD4 signaling.

Authors:  Poyil Pratheeshkumar; Young-Ok Son; Sasidharan Padmaja Divya; Lilia Turcios; Ram Vinod Roy; John Andrew Hitron; Lei Wang; Donghern Kim; Jin Dai; Padmaja Asha; Zhuo Zhang; Xianglin Shi
Journal:  Oncotarget       Date:  2016-08-09

7.  Programmed cell death 4 (PDCD4) as a novel prognostic marker for papillary thyroid carcinoma.

Authors:  Francesca Galuppini; Matteo Fassan; Loris Bertazza; Susi Barollo; Luciano Cascione; Sara Watutantrige-Fernando; Vanni Lazzarin; Paolo Simonato; Federica Vianello; Massimo Rugge; Caterina Mian; Gianmaria Pennelli
Journal:  Cancer Manag Res       Date:  2019-08-20       Impact factor: 3.989

8.  Papillary Thyroid Carcinoma: Molecular Distinction by MicroRNA Profiling.

Authors:  Francesca Galuppini; Simona Censi; Isabella Merante Boschin; Matteo Fassan; Marta Sbaraglia; Nicola Valeri; Jens Claus Hahne; Loris Bertazza; Giada Munari; Marco Galasso; Luciano Cascione; Susi Barollo; Massimo Rugge; Federica Vianello; Angelo Paolo Dei Tos; Caterina Mian; Gianmaria Pennelli
Journal:  Front Endocrinol (Lausanne)       Date:  2022-02-23       Impact factor: 5.555

9.  Quercetin inhibits Cr(VI)-induced malignant cell transformation by targeting miR-21-PDCD4 signaling pathway.

Authors:  Poyil Pratheeshkumar; Young-Ok Son; Sasidharan Padmaja Divya; Lei Wang; Lilia Turcios; Ram Vinod Roy; John Andrew Hitron; Donghern Kim; Jin Dai; Padmaja Asha; Zhuo Zhang; Xianglin Shi
Journal:  Oncotarget       Date:  2016-06-17
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.